Clinical trials: Memory, Delayed
Healthy
Efficacy and Safety of Acute Topical and Aromatic Essential Oil-Based Products for Cognitive Support
This study will evaluate whether the InTune product system may help support attention, memory, focus, and other thinking skills in healthy adults ages 18-64.
- Trial name
- ITS (NCT07623811)
- Testing
- Cognitive Support System
- Where
- United States
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- dōTERRA International
Alzheimer Disease, Cognition Disorders
Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)
This phase IIIb trial is a prospective, randomized, double-blind, placebo-controlled, 36-month study comparing the length of time of progression from mild cognitive impairment (MCI) to a clinical diagnosis of Alzheimer's disease…
- Trial name
- NCT00000174
- Testing
- Rivastigmine
- Where
- 15 sites in United States
- Sponsor
- Novartis
Schizophrenia, Psychotic Disorders
Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone
To assess the effect of risperidone 2 mg daily (QD) on the differential sensitivity of 2 spatial working memory tests (the GMLT and MDR) in non-agitated, drug-naive patients suffering from first-episode…
- Trial name
- NCT00174200
- Testing
- Risperidone 2 mg
- Where
- 3 sites in Canada, Russia
- Volunteers
- 20 people
- Sponsor
- Pfizer
Alzheimer's Disease
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
The main purpose of this study is to evaluate the efficacy of the study drug known as lanabecestat in participants with mild Alzheimer's disease (AD) dementia.
- Trial name
- DAYBREAK-ALZ (NCT02783573)
- Testing
- Lanabecestat
- Where
- 262 sites in United States, Canada and 16 more
- Volunteers
- 1,722 people
- Sponsor
- AstraZeneca
Alzheimer's Disease
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
This study is an extension of study I8D-MC-AZES (NCT02245737), the AMARANTH study. The purpose of this study is to evaluate the effectiveness of the study drug lanabecestat in participants with early Alzheimer's disease dementia…
- Trial name
- NCT02972658
- Testing
- Lanabecestat
- Where
- 133 sites in United States, Australia and 12 more
- Volunteers
- 421 people
- Sponsor
- AstraZeneca